Active, Not Recruiting
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
NCT02787369
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- Dana Farber Cancer Institute Boston, Massachusetts, United States